EC pledges 4.9bn to grant access to medicines
Under the Coronavirus Global Response Framework, the European Commission is allocating further 4.9bn to assure access to COVID-19 countermeasures for poor countries.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1342 entries already.
Entries by Thomas Gabrielczyk
BioGeneration Ventures closes BGV IV Fund at 105m
/in News/by Thomas GabrielczykBioGeneration Ventures has closed its fourth VC fund for European start-ups (BGV IV) at 105m.
LSP leads 11m Series A round in OneProject
/in News/by Thomas GabrielczykOneProjects Ltd, an Irish-German cardiac imaging specialist, has closed an 11m Series A financing led by Amsterdam-headquartered life sciences investor LSP.
Illumina and Epidarex Capital invest in post-Brexit UK
/in News/by Thomas GabrielczykIllumina has opened its first accelerator outside the US in Cambridge to fund genomics start-ups. Meanwhile, Epidarex Capital has raised £102m for UK biotechs.
Novel adjuvant teases T cells to respond to HCV
/in News/by Thomas GabrielczykResearchers from Italy, Denmark and the UK have devised a new vaccination strategy to tackle hepatitis C and boosting the required strong T cell response.
First drug found to reduce COVID-19-mortality
/in News/by Thomas GabrielczykA clinical trial has identified the first immuno-modulatory drug to significantly reduce COVID-19 mortality in ventilated patients.
Germany puts 300m in CureVac AG for COVID-19 vaccine
/in News/by Thomas GabrielczykIn the race aimed at securing access to COVID-19 vaccines, Germany has acquired a minority stake in the local mRNA vaccine producer Curevac AG.
Abbvie and Genmab team up in oncology
/in News/by Thomas GabrielczykAbbVie is partnering with Genmab A/S to commercialise up to seven new antibody formats.
Evox Therapeutics signs US$1.2bn deal with Eli Lilly
/in News/by Thomas GabrielczykEvox Therapeutics Ltd has licenced its exosome-based RNAi/antisense RNA delivery technology to Eli Lilly to target selected neurological diseases.
Calliditas Therapeutics raise US$90m in Nasdaq IPO
/in News/by Thomas GabrielczykSwedish budenoside formulation specialist Calliditas Therapeutics AB has successfully raised US$90m in an oversubscribed NASDAQ IPO.